Generic placeholder image

Current Analytical Chemistry

Editor-in-Chief

ISSN (Print): 1573-4110
ISSN (Online): 1875-6727

Research Article

RP-UFLC based Bioanalytical Method Development, Optimization, and Validation for the Estimation of Isradipine in Rabbit Serum

Author(s): Debashish Ghose, Suryakanta Swain*, Chinam Niranjan Patra and Bikash Ranjan Jena

Volume 19, Issue 5, 2023

Published on: 22 June, 2023

Page: [403 - 416] Pages: 14

DOI: 10.2174/1573411019666230605112048

Price: $65

conference banner
Abstract

Introduction: The objective of this study is to provide a rapid, sensitive, consistent, and costeffective method for quantifying isradipine using ultra-fast liquid chromatography.

Methods: Quality by Design principles will form the basis of this approach, grounded on response surface analysis. Shimadzu liquid chromatographic system equipped with a photodiode array detector and LC solution software was used to conduct the RP-UFLC method development and validation. An ODS C18 (250 x 4.6 mm; 5 μm) UFLC column was used to complete the analysis. The RSM methodology utilized a central composite design to perform the optimization studies.

Results: The mobile phase ratio and flow rate were considered crucial method parameters, as well as the peak area, retention time, and USP plate were considered critical analytical attributes. The optimal conditions for chromatographic separation were followed using 80% acetonitrile and water (20% v/v) as mobile phase, a 1 mL/min flow rate, an injection volume of 20 μL, 40°C of column oven temperature, and maximum absorption at λmax 254 nm using graphical optimization technique. When examining concentrations between 5 and 150 ng/mL, linearity was observed with an R2 of 0.999. The method created was validated by employing stability testing per the recommendations provided by ICH Q2 (R1). The analysis of blood serum was modified so that it could be used to examine the pharmacokinetic parameters.

Conclusion: As a result, high accuracy, precision, sensitivity, linearity, and robustness were established for predicting the amount of isradipine present in its freeze-dried nano-formulations.

Keywords: Critical process parameters, critical analytical attributes, critical method parameters, pharmacokinetics, stability, isradipine.

Graphical Abstract
[1]
Doat, M.; Hacot, J.P.; Pavin, D.; Righetti, A. Cardiac function improvement 24 hours after isradipine SRO in patients with chronic stable angina: A double-blind randomized study. Acta Cardiol., 1996, 51(2), 155-164.
[PMID: 8742912]
[2]
Hansson, L.; Lindholm, L.H.; Ekbom, T.; Dahlöf, B.; Lanke, J.; Scherstén, B.; Wester, P-O.; Hedner, T.; de Faire, U. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish trial in old patients with Hypertension-2 study. Lancet, 1999, 354(9192), 1751-1756.
[http://dx.doi.org/10.1016/S0140-6736(99)10327-1] [PMID: 10577635]
[3]
Fitton, A.; Benfield, P. Isradipine. Drugs, 1990, 40(1), 31-74.
[http://dx.doi.org/10.2165/00003495-199040010-00004] [PMID: 2143980]
[4]
Rees, K.; Stowe, R.; Patel, S.; Ives, N.; Breen, K.; Ben-Shlomo, Y.; Clarke, C.E. Anti-hypertensive drugs as disease-modifying agents for Parkinson’s disease: Evidence from observational studies and clinical trials. Cochrane Libr., 2011, 9(11), CD008535.
[http://dx.doi.org/10.1002/14651858.CD008535.pub2] [PMID: 22071852]
[5]
Tse, F.L.S.; Jaffe, J.M. Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man. Eur. J. Clin. Pharmacol., 1987, 32(4), 361-365.
[http://dx.doi.org/10.1007/BF00543970] [PMID: 2956112]
[6]
Christensen, H.R.; Antonsen, K.; Simonsen, K.; Lindekaer, A.; Bonde, J.; Angelo, H.R.; Kampmann, J.P. Bioavailability and pharmacokinetics of isradipine after oral and intravenous administration: Half-life shorter than expected? Pharmacol. Toxicol., 2000, 86(4), 178-182.
[http://dx.doi.org/10.1034/j.1600-0773.2000.860405.x]
[7]
Glifton, G.D.; Blouin, R.A.; Dilea, C.; Schran, H.F.; Hassell, A.E.; Gonasun, L.M.; Foster, T.S. The pharmacokinetics of oral isradipine in normal volunteers. J. Clin. Pharmacol., 1988, 28, 36-42.
[http://dx.doi.org/10.1002/j.1552-4604.1988.tb03098.x]
[8]
Christensen, H.R.; Simonsen, K.; Kampmann, J.P. Pharmacokinetics and dynamic response of plain and slow release isradipine formulations in moderately hypertensive patients. Pharmacol. Toxicol., 1993, 73, 279-284.
[http://dx.doi.org/10.1111/j.1600-0773.1993.tb00585.x]
[9]
Christensen, H.R.; Angelo, H.R.; Skajaa, K. Determination of isradipine and its pyridine metabolite in serum by capillary column gas chromatography with nitrogen selective detection. J. Chromatign, 1992, 574(1), 161-165.
[http://dx.doi.org/10.1016/0378-4347(92)80113-5]
[10]
Laplanche, R.; Fertil, B.; Nüesch, E.; Jais, J-P.; Niederberger, W.; Steimer, J-L.; Steimer, J.L. Exploratory analysis of population pharmacokinetic data from clinical trials with application to isradipine. Clin. Pharmacol. Ther., 1991, 50(1), 39-54.
[http://dx.doi.org/10.1038/clpt.1991.102]
[11]
Boutagy, J.; Rumble, F.; Dunagan, F. Determination of isradipine and the oxidative pyridine metabolite in human plasma by high-performance liquid chromatography. J. Chromatogr., Biomed. Appl., 1989, 487(2), 483-488.
[http://dx.doi.org/10.1016/S0378-4347(00)83059-5] [PMID: 2524499]
[12]
Bobbala, S.K.R.; Veerareddy, P.R. Formulation, evaluation, and pharmacokinetics of isradipine proliposomes for oral delivery. J. Liposome Res., 2012, 22(4), 285-294.
[http://dx.doi.org/10.3109/08982104.2012.697067] [PMID: 22762199]
[13]
Johnson, B.A.; Javors, M.A.; Lam, Y.W.F.; Wells, L.T.; Tiouririne, M.; Roache, J.D.; Ait-Daoud, N.; Lawson, K. Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2005, 29(1), 15-20.
[http://dx.doi.org/10.1016/j.pnpbp.2004.08.014] [PMID: 15610940]
[14]
Takamura, K.; Kusu, F.; Abdel-Wadood, H.; El-Rabbat, N.; Saleh, G.; Refaat, I. Redox properties of isradipine and its electrochemical detection in the HPLC determination of the compound in human serum. Biomed. Chromatogr., 2000, 14(7), 453-458.
[http://dx.doi.org/10.1002/1099-0801(200011)14:7<453:AID-BMC5>3.0.CO;2-7] [PMID: 11113923]
[15]
Ghose, D.; Patra, C.N.; Ravi Kumar, B.V.V.; Swain, S.; Jena, B.R.; Choudhury, P.; Shree, D. QbD-based formulation optimization and characterization of polymeric nanoparticles of cinacalcet hydrochloride with improved biopharmaceutical attributes. Turk. J. Pharm. Sci., 2021, 18(4), 452-464.
[http://dx.doi.org/10.4274/tjps.galenos.2020.08522] [PMID: 34496552]
[16]
Q8(R2): Pharmaceutical Development. 2009. Available From: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm
[17]
Jena, B.R.; Panda, S.P.; Kulandaivelu, U.; Alavala, R.R.; Rao, G.S.N.K.; Swain, S.; Pattnaik, G.; Ghose, D. A QbD driven development of an RP-HPLC method for the quantitation of abiraterone acetate for its pharmaceutical formulations in the presence of degradants. Turk. J. Pharm. Sci., 2021, 18(6), 718-729.
[http://dx.doi.org/10.4274/tjps.galenos.2021.74150] [PMID: 34978401]
[18]
Manwar, J.V.; Vispute, S.S.; Kumbhar, D.D.; Manmode, R.S.; Bakal, R.L.; Jadhao, R.G.; Jogdand, S.D. Response surface based optimization of system variables for liquid chromatographic analysis of candesartan cilexetil. J. Taibah Univ. Sci., 2017, 11(1), 159-172.
[http://dx.doi.org/10.1016/j.jtusci.2016.02.004]
[19]
Jena, B.R.; Panda, S.P.; Umasankar, K.; Swain, S.; Koteswara Rao, G.S.N.; Damayanthi, D.; Ghose, D.; Pradhan, D.P. Applications of QbDbased software’s in analytical research and development. Curr. Pharm. Anal., 2021, 17(4), 461-473.
[http://dx.doi.org/10.2174/1573412916666200108155853]
[20]
Jena, B.R.; Panda, S.P.; Umasankar, K.; Alavala, R.R.; Rao, K.G.; Swain, S.; Pattnaik, G.; Ghose, D.; Pradhan, D.P. Analytical QbD based systematic development of a novel RP-UHPLC method for the quantification of albuterol sulphate in its metered dose inhaler formulations. J. Res. Pharm., 2021, 25, 689-701.
[21]
Panchumarthy, R.; Navya, C.N.; Pravallika, D.; Navya, S.D. A review on step-by-step analytical method validation. IOSR J. Pharm., 2015, 5, 7-19.
[22]
Crowther, J.B. Validation of pharmaceutical test methods.Handbook of Modern Pharmaceutical Analysis; Academic Press: New York, 2001, pp. 415-443.
[23]
Park, J.H.; Park, Y.S.; Rhim, S.Y.; Jhee, O.H.; Kim, S.H.; Yang, S.C.; Lee, M.H.; Shaw, L.M.; Kang, J.S. Quantification of isradipine in human plasma using LC–MS/MS for pharmacokinetic and bioequivalence study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2009, 877(1-2), 59-64.
[http://dx.doi.org/10.1016/j.jchromb.2008.11.021] [PMID: 19041284]
[24]
Beg, S.; Swain, S.; Jena, B.R. Design of experiments for pharmaceutical product development. Design of experiments for the development of solid oral dosage forms; Sringer, 2021, pp. 19-26.
[http://dx.doi.org/10.1007/978-981-33-4351-1_2]
[25]
Someshwar, K.; Swain, S.; Rao, M.E.B.; Jena, B.R.; Unnam, S.; Dasia, V. QbD-based design and characterization of mucoadhesive microspheres of quetiapine fumarate with improved oral bioavailability and brain biodistribution potential. Bull. of Facul. Pharm., 2018, 56, 129-145.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy